Journal
CURRENT OPINION IN VIROLOGY
Volume 14, Issue -, Pages 79-86Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.coviro.2015.08.014
Keywords
-
Categories
Funding
- Hastings Foundation
- Fletcher Jones Foundation
- Cancer Research Switzerland [KFS-3234-08-2013]
- Worldwide Cancer Research [14-1033]
- University of Zurich
- Sobek Foundation
- Fondation Acteria
- Swiss Vaccine Research Institute
- SNF [310030_143979, CRSII3_136241]
- [CA82057]
- [CA31363]
- [CA115284]
- [CA180779]
- [DE023926]
- [HL110609]
- [AI073099]
- [AI116585]
Ask authors/readers for more resources
Human gamma-herpesviruses contain Epstein Barr virus (EBV), the first human tumor virus that was identified in man, and Kaposi Sarcoma associated herpesvirus (KSHV), one of the most recently identified human oncogenic pathogens. Both of these have co-evolved with humans to cause tumors only in a minority of infected individuals, despite their exquisite ability to establish persistent infections. In this review we will summarize the fine-tuned balance between immune responses, immune escape and cellular transformation by these viruses, which results in life-long persistent, but asymptomatic infection with immune control in most virus carriers. A detailed understanding of this balance is required to immunotherapeutically reinstall it in patients that suffer from EBV and KSHV associated malignancies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available